Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (6572)	6/24/1998 7:41:00 AM
From: Robert K.	Respond to of 17367

I predict the true potential of rBPI21 will not be apparent in clinical trials. IMO the true potential will become apparent once bpi is approved and is allowed to be used ASAP without time delay. It pays to discover. VBG

To: Robert K. who wrote (6572)	6/24/1998 2:12:00 PM
From: Starlight	Read Replies (2) \| Respond to of 17367

Regarding disclosure -- I agree with Robert. I think you're blowing things somewhat out of proportion. Most heads of companies are very anxious to get the "story" out about how great their company is doing, HOWEVER, writing up a press release on every detail of the company's business is just not wise, nor is it necessary. The lawyers in most companies are very cautious about putting things in print that 1)might reveal proprietary information 2)might make claims that haven't been properly substantiated 3)might require too much "explanation" that would be ambiguous, etc. 4)might raise some doubts in investors minds 5)can't be thoroughly explained from a lay point of view. I'm sure I've omitted some reasons, but it all boils down to being very cautious because of the litigious, competitive environment we live in today. Having worked in PR myself at one time, I can tell you that I wasn't even allowed to attend Executive Staff meetings. I was only told what "I needed to know." The same pretty much applies now regarding many company's attitudes toward shareholders. Betty